Your browser doesn't support javascript.
loading
Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics.
Hori, Hikaru; Yasui-Furukori, Norio; Hasegawa, Naomi; Iga, Jun-Ichi; Ochi, Shinichiro; Ichihashi, Kayo; Furihata, Ryuji; Kyo, Yoshitaka; Takaesu, Yoshikazu; Tsuboi, Takashi; Kodaka, Fumitoshi; Onitsuka, Toshiaki; Okada, Tsuyoshi; Murata, Atsunobu; Kashiwagi, Hiroko; Iida, Hitoshi; Hashimoto, Naoki; Ohi, Kazutaka; Yamada, Hisashi; Ogasawara, Kazuyoshi; Yasuda, Yuka; Muraoka, Hiroyuki; Usami, Masahide; Numata, Shusuke; Takeshima, Masahiro; Yamagata, Hirotaka; Nagasawa, Tatsuya; Tagata, Hiromi; Makinodan, Manabu; Kido, Mikio; Katsumoto, Eiichi; Komatsu, Hiroshi; Matsumoto, Junya; Kubota, Chika; Miura, Kenichiro; Hishimoto, Akitoyo; Watanabe, Koichiro; Inada, Ken; Kawasaki, Hiroaki; Hashimoto, Ryota.
Afiliação
  • Hori H; Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
  • Yasui-Furukori N; Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, Japan.
  • Hasegawa N; National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
  • Iga JI; Department of Neuropsychiatry Molecules and Function, Ehime University Graduate School of Medicine, Matsuyama, Japan.
  • Ochi S; Department of Neuropsychiatry Molecules and Function, Ehime University Graduate School of Medicine, Matsuyama, Japan.
  • Ichihashi K; Department of Neuropsychiatry, University of Tokyo Hospital, Tokyo, Japan.
  • Furihata R; Agency for Student Support and Disability Resources, Kyoto University, Kyoto, Japan.
  • Kyo Y; Department of Psychiatry, School of Medicine, Kitasato University, Tokyo, Japan.
  • Takaesu Y; Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.
  • Tsuboi T; Department of Neuropsychiatry, Kyorin University School of Medicine, Mitaka, Japan.
  • Kodaka F; Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan.
  • Onitsuka T; Department of Neuroimaging Psychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Okada T; Department of Psychiatry, Jichi Medical University, Tochigi, Japan.
  • Murata A; National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
  • Kashiwagi H; National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
  • Iida H; Department of Psychiatry, National Center of Neurology and Psychiatry Hospital, Kodaira, Japan.
  • Hashimoto N; Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
  • Ohi K; Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
  • Yamada H; Department of Psychiatry, Gifu University Graduate School of Medicine, Gifu, Japan.
  • Ogasawara K; National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
  • Yasuda Y; Department of Neuropsychiatry, Hyogo College of Medicine, Nishinomiya, Japan.
  • Muraoka H; Center for Postgraduate Clinical Training and Career Development, Nagoya University Hospital, Nagoya, Japan.
  • Usami M; National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
  • Numata S; Life Grow Brilliant Mental Clinic, Medical Corporation Foster, Osaka, Japan.
  • Takeshima M; Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan.
  • Yamagata H; Department of Child and Adolescent Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa, Japan.
  • Nagasawa T; Department of Psychiatry, Graduate School of Biomedical Science, Tokushima University, Tokushima, Japan.
  • Tagata H; Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.
  • Makinodan M; Division of Neuropsychiatry, Department of Neuroscience, Yamaguchi University School of Medicine, Yamaguchi, Japan.
  • Kido M; Department of Neuropsychiatry, Kanazawa Medical University, Uchinada, Japan.
  • Katsumoto E; Department of Neuropsychiatry, Toho University Graduate School of Medicine, Tokyo, Japan.
  • Komatsu H; Department of Psychiatry, Nara Medical University School of Medicine, Kashihara, Japan.
  • Matsumoto J; Toyama City Hospital, Toyama, Japan.
  • Kubota C; Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.
  • Miura K; Katsumoto Mental Clinic, Oosaka, Japan.
  • Hishimoto A; Department of Psychiatry, Tohoku University Hospital, Sendai, Japan.
  • Watanabe K; National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
  • Inada K; Department of Psychiatry, National Center of Neurology and Psychiatry Hospital, Kodaira, Japan.
  • Kawasaki H; National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
  • Hashimoto R; Department of Psychiatry, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Front Psychiatry ; 13: 823826, 2022.
Article em En | MEDLINE | ID: mdl-35656353
ABSTRACT
In several clinical guidelines for schizophrenia, long-term use of anticholinergic drugs is not recommended. We investigated the characteristics of the use of anticholinergics in patients with schizophrenia by considering psychotropic prescription patterns and differences among hospitals. A cross-sectional, retrospective prescription survey at the time of discharge was conducted on 2027 patients with schizophrenia from 69 Japanese hospitals. We examined the relations among psychotropic drug prescriptions regarding anticholinergic prescription. We divided the hospitals into three groups-low rate group (LG), medium rate group (MG), and high rate group (HG)-according to their anticholinergic prescription rates, and analyzed the relationship between anticholinergic prescription rates and antipsychotic prescription. Anticholinergic drugs were prescribed to 618 patients (30.5%), and the prescription rates were significantly higher for high antipsychotic doses, antipsychotic polypharmacy, and first-generation antipsychotics (FGAs) use. The anticholinergic prescription rate varied considerably among hospitals, ranging from 0 to 66.7%, and it was significantly higher in patients with antipsychotic monotherapy, antipsychotic polypharmacy, and normal and high doses of antipsychotics in HG than in those LG and MG. The anticholinergics prescription rate in patients with second-generation antipsychotic monotherapy in HG was also significantly higher than in those LG and MG; however, the difference was no longer significant in patients with FGA monotherapy. Conclusively, in addition to high antipsychotic doses, antipsychotic polypharmacy, and FGA use, hospital characteristics influence the prescribing of anticholinergic drugs.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Qualitative_research Idioma: En Revista: Front Psychiatry Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Qualitative_research Idioma: En Revista: Front Psychiatry Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão